$NTRA

Brophy Michael Burkes sold $216K of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 795 shares of Natera, Inc. (NTRA) at an average of $271.74 ($267.99–$274.22, $0.22M total) across 2 trades over 2026-08-03 to 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed open-market sale reduces the insider’s direct holdings but does not, by itself, imply new information about Natera’s near-term fundamentals.

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but the 10b5-1 framing lowers the signal strength.

03

What to watch

The article does not state whether other insiders sold/bought around the same window, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed Aug 5, covering sales executed Aug 3 to Aug 4

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc., reported by the CFO.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CFO Brophy Michael Burkes sold about $216K of NTRA shares via a 10b5-1 plan on Aug 3 to Aug 4.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with stated 10b5-1 pre-arrangement, and the article provides no accompanying earnings, guidance, or operational developments.

Market effects

Minimal; insider sales under 10b5-1 typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO insider sale is disclosed in the Form 4.

  • Brophy Michael Burkes

    Natera CFO who executed the reported open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.